Table 2.
Metastatic pancreatic ductal adenocarcinoma: palliative second-line regimens
| Regiment | Phase | n | mPFS (months) |
mOS (months) |
DCR (%) |
References |
|---|---|---|---|---|---|---|
| Second-line therapy (mostly after gemcitabine mono in first-line treatment) | ||||||
| Nal-Iri/5-FU/LV (NAPOLI-1 trial) | III | 236 | 3.1 | 6.1 | n.a | [33] |
| 5-FU/LV | 1.5 | 4.2 | ||||
| OFF (CONKO-003 trial) | III | 160 | 2.9 | 5.9 | n.a | [35] |
| 5-FU/LV | 2.0 | 3.3 | ||||
| mFOLFOX6, (PANCREOX trial) | III | 108 | 3.1 | 6.1 | 44.7 | [37] |
| 5-FU/LV | 2.9 | 9.9 | 55.3 | |||
| Gemcitabine/nab-paclitaxel (after FOLFIRINOX) | Cohort | 57 | 5.1 | 8.8 | 58 | [39] |
mPFS median progression-free survival, mOS median overall survival, DCR disease control rate, OFF oxaliplatin, leucovorin, 5-FU, LV leucovorin, 5-FU 5-FU, nal-Iri nanoliposomal irinotecan, FOLFIRI 5-FU, leucovorin, irinotecan, FOLFOX 5-FU, leucovorin, oxaliplatin